Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/43067
Title: | Acoramidis in Transthyretin Amyloid Cardiomyopathy | Authors: | VERBEECK, Johan De Backer, Mickael BUYSE, Marc |
Issue Date: | 2024 | Publisher: | MASSACHUSETTS MEDICAL SOC | Source: | NEW ENGLAND JOURNAL OF MEDICINE, 390 (14) , p. 1345 -1347 | Abstract: | To the Editor: In a phase 3 trial of acoramidis for transthyretin amyloid cardiomyopathy, Gillmore et al. (Jan. 11 issue)(1) used the Finkelstein-Schoenfeld test to assess the hierarchical composite primary outcome. They expressed the treatment effect as a win ratio, thereby following the initial presentation of the analysis of a prioritized outcome.(2) However, the generalized pairwise comparison method, to which the Finkelstein-Schoenfeld test and the win ratio belong, has evolved substantially since this first application.(3) To aid the interpretation of the results, it is now recommended that the proportions of wins and losses for each outcome are reported to understand the . . . | Notes: | Verbeeck, J (corresponding author), Hasselt Univ, Hasselt, Belgium. johan.verbeeck@uhasselt.be |
Document URI: | http://hdl.handle.net/1942/43067 | ISSN: | 0028-4793 | e-ISSN: | 1533-4406 | DOI: | 10.1056/NEJMc2401669 | ISI #: | 001217044600003 | Rights: | 2024 Massachusetts Medical Society. All rights reserved. | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
24-01414_Proof_hi.pdf Until 2024-10-10 | Peer-reviewed author version | 116.36 kB | Adobe PDF | View/Open Request a copy |
Verbeeck_NEJM.pdf Restricted Access | Published version | 316.82 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.